Tuesday, January 17, 2017 12:35:10 PM
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.
Ronald Orol Ronald Orol Follow Jan 17, 2017 9:59 AM EST
Insurgent fund manager Jana Partners' Barry Rosenstein recently acquired a large stake in the New York-based pharmaceutical company, according to a person familiar with the situation. He noted that the investment, which is a top position for the fund, was disclosed privately to Rosenstein's investors in a risk report. The report, however, didn't provide any commentary on the position.
EDITOR'S NOTE: This article was originally published by The Deal, a sister publication of TheStreet that offers sophisticated insight and analysis on all types of deals, from inception to integration. Click here for a free trial.
Nevertheless, Jana Partners frequently has launched campaigns and proxy contests, suggesting that one could be forthcoming, especially considering that Rosenstein hasn't initiated a new campaign in several months. According to FactSet, Jana Partners has threatened proxy contests at nine companies, engaged in director-election battles at seven companies and launched 38 campaigns overall since 2001.
All that suggests Rosenstein, an early employer of the activist tactic, could launch a contest at Bristol-Myers to press for some strategic options, in advance of a Feb. 2 deadline to nominate dissident director candidates for the company's 2017 annual meeting, expected in May.
There are a wide variety of strategic options available to Rosenstein and his team should they decide to agitate publicly or privately.
Steve Chesney, analyst at Atlantic Equities, said Rosenstein or another activist fund could take issue with what he sees as Bristol-Myers 's over-concentrated portfolio and its over-focus on one drug, blockbuster cancer therapy Opdivo. He suggested the company could be pressed to make acquisitions or invest more heavily in business development so it can become more diversified.
"Bristol is highly dependent on the outlook for one drug, Opdivo," Chesney said. "To support its revenue base, given the risk of competition in the immuno-oncology space, the prudent strategy would be to expand by acquisitions or alliances and partnerships with mid-stage or later-stage therapeutic development candidates."
Chesney estimates that roughly 30% of Bristol's 2020 revenue base, unless changes are made, will be driven by Opdivo.
Kurt Kemper, analyst at Hillard Lyons, agrees. He notes Bristol-Myers has said it is seeking to maintain a diversified portfolio within and outside of the immune-oncology space as part of its key strategies going forward. Nevertheless, Kemper suggests that Bristol-Myers should consider diversifying through acquisitions to help reduce its risk profile, given its heavy reliance on Opdivo.
He added that the drug company could make smaller acquisitions in the immuno-oncology space or even a larger transformative type deal outside of that space.
"We believe success in diversification outside of immuno-oncology is important for the company's risk profile, given the increasing competitiveness in the area," Kemper said.
Activists often pressure companies to be sold too. As a result, Jana Partners or another activist also could pressure Bristol to be acquired by another drug company. The pharmaceutical space is expected to see high levels of M&A activity in 2017, especially with the election of Donald Trump clearing away a lot of the regulatory hurdles to mega-drug sector M&A.
David Katz, founder of $760 million value investment firm $760 million Matrix Asset Advisors, said he expects a lot of M&A in the drug company and health care space in 2017. Katz, who is a contributor to Real Money, noted Pfizer (PFE) , Merck (MRK) , Johnson & Johnson (JNJ) or Novartis (NVS) are all capable of acquiring Bristol-Myers. He added that Bristol-Myers's large immune-oncology drug portfolio, led by Opdivo, could make it an attractive candidate to any of the largest global pharmaceutical companies. "There are only a few companies big enough that would be capable of making an acquisition of Bristol," he said.
Last week, for instance, Pfizer CFO Frank D'Amelio told a J.P. Morgan Healthcare conference that he expects more tuck-in and bolt-on acquisitions for the overall industry, adding that he thought large-scale M&A was possible.
Chesney also acknowledged that there has been "persistent chatter, given some of the excitement around the world of immuno-oncology," that Bristol-Myers Squibb could become a target for acquisition.
However, he suggested that the most capable buyers may not be interested. Johnson & Johnson hasn't pursued large scale commercial transactions in the pharmaceutical space and is already quite diversified in with operations involving drugs, medical devices and consumer products. He added that Johnson & Johnson is more focused on make smaller development stage asset acquisitions, suggesting it wouldn't want to make the kind of transformative acquisition a Bristol purchase would entail.
Chesney added that he thought it was unlikely that Merck, the closest competitor to Bristol in the oncology business, would have any interest, largely because the two companies already overlap significantly.
The most widely speculated potential buyer for Bristol-Myers is Pfizer - many analysts and investors contend that the New York based company would see more of a benefit in acquiring Bristol.
Chesney contends that while Pfizer has clearly expressed interest in similar assets in the past, its willingness to enter into a significant transaction for Bristol-Myers could be limited by the shifting sands in the immuno-oncology space as well as Pfizer's own efforts to develop an in-house program, including a partnership with German-based Merck KGaA.
____________________________________________
https://www.thestreet.com/story/13955786/1/why-bristol-myers-squibb-may-be-a-merger-target-soon.html
BMY
Recent BMY News
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... • Business Wire • 05/06/2024 10:59:00 AM
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/06/2024 10:59:00 AM
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • PR Newswire (US) • 04/29/2024 10:00:00 AM
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 04/26/2024 10:59:00 AM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Bristol Myers Squibb Reports First Quarter Financial Results for 2024 • Business Wire • 04/25/2024 10:59:00 AM
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 04/08/2024 03:30:00 PM
- Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy • Business Wire • 04/05/2024 01:05:00 PM
- European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) • Business Wire • 04/03/2024 12:08:00 AM
- Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals • Business Wire • 04/02/2024 10:59:00 AM
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… • Business Wire • 03/28/2024 08:05:00 PM
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease • Business Wire • 03/28/2024 08:01:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
- Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma • Business Wire • 03/20/2024 08:45:00 PM
- Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma • Business Wire • 03/20/2024 10:59:00 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM